PMID- 26125212
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20181203
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 95
IP  - 6
DP  - 2015 Jun
TI  - Imiquimod-induced subacute cutaneous lupus erythematosus-like changes.
PG  - 349-51
AB  - Imiquimod is a topical immunomodulator used to treat genital warts and cutaneous 
      malignancies that exerts its effects via induction of proinflammatory cytokines 
      through activation of toll-like receptor (TLR) 7. Although subacute cutaneous 
      lupus erythematosus (SCLE) has been reported in association with multiple 
      systemic medications, SCLE in patients treated with topical agents has not been 
      widely reported. We report the case of a 50-year-old woman with local induction 
      of lesions that clinically and histologically resembled SCLE following treatment 
      with topical imiquimod.
FAU - Maguiness, Sheilagh M
AU  - Maguiness SM
FAU - Farsani, Terry T
AU  - Farsani TT
AD  - Palo Alto Medical Foundation, 701 E El Camino Real, Mountain View, CA 94306, USA. 
      tfarsani@gmail.com.
FAU - Zedek, Daniel C
AU  - Zedek DC
FAU - Berger, Timothy G
AU  - Berger TG
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Aminoquinolines)
RN  - 0 (Immunologic Factors)
RN  - P1QW714R7M (Imiquimod)
SB  - IM
MH  - Aminoquinolines/*adverse effects
MH  - Female
MH  - Humans
MH  - Imiquimod
MH  - Immunologic Factors/*adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/pathology
MH  - Middle Aged
EDAT- 2015/07/01 06:00
MHDA- 2015/09/12 06:00
CRDT- 2015/07/01 06:00
PHST- 2015/07/01 06:00 [entrez]
PHST- 2015/07/01 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
PST - ppublish
SO  - Cutis. 2015 Jun;95(6):349-51.